Molecular Detection of Microsporidia in Colorectal Cancer Patients Based on Screening of Pre‐ and Postoperative Gastrointestinal and Respiratory Samples
Аннотация
ABSTRACT Colorectal cancer (CRC) treatments cause immunosuppression, increasing susceptibility to opportunistic infections. Microsporidia are intracellular fungi, but their role during CRC treatment remains unclear. This longitudinal study investigated Microsporidia dynamics in CRC patients and healthy controls. Stool, sputum, and saliva samples were collected from 150 CRC patients preoperatively and at first and third postoperation months, and from 148 healthy controls. Microsporidia were evaluated by microscopy and species‐specific real‐time PCR, and clinical associations were analyzed. Microsporidia DNA was detected by PCR in 15 of 150 CRC patients (10.0%) preoperatively, compared with 2 of 148 healthy controls (1.35%; p = 0.002), whereas all samples were negative by microscopy. Enterocytozoon bieneusi was the most frequently detected species. A higher detection frequency was observed in patients with advanced‐stage disease. During follow‐up, the prevalence of Microsporidia DNA was 1.3% (2/149) at the first postoperative month and 6.8% (10/148) at the third postoperative month, when most patients were receiving chemotherapy. In conclusion, Microsporidia DNA was detected more frequently in CRC patients than healthy individuals. Increased postoperative detection may reflect chemotherapy‐associated immunosuppression. Molecular screening may facilitate the detection of Microsporidia DNA during CRC follow‐up. Further studies are warranted to clarify the potential role of Microsporidia in CRC.